Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature Medicine 14, 249 - 250 (2008)
doi:10.1038/nm0308-249
Reducing glutamate signaling pays off in fragile X
Gary J Bassell1 & Christina Gross1
- Gary J. Bassell is associate professor in the Departments of Cell Biology and Neurology and Christina Gross is postdoctoral fellow in the Department of Cell Biology, Whitehead Biomedical Research Building #415, Emory University School of Medicine, 615 Michael Street, Atlanta, Georgia 30322, USA. e-mail: gbassel@emory.edu
Abstract
A recent theory about the basis for fragile X syndrome is now validated in a mouse model. The findings point the way to treatment options targeting group 1 metabotropic glutamate receptors.
Basic science on disease mechanisms is driven by hypotheses that persist long enough to be frequently disproved or complicated by tests of principle in animal models. Rarely, but all the more compellingly, a scientific model derived from basic research turns out to be appropriate for actual medical therapy in people.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stabilityNature Neuroscience Article (01 May 2007)
Identification of small molecules rescuing fragile X syndrome phenotypes in DrosophilaNature Chemical Biology Article (01 Apr 2008)
